Related Experiment Video
Updated: May 14, 2026

Frailty Assessment in an Aging Mouse Model
Published on: September 23, 2025
Design and Rationale of the FICAPP Study: Frailty in Cardiac Amyloidosis: Profiling the Phenotype
Elyn Montgomery1, Natasha Gorrie2, Georgia McCaughan3
1St Vincent's Hospital, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; University of Technology Sydney, Sydney, NSW, Australia.
Background & Aim:
Cardiac amyloidosis is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Frailty, a biologic syndrome of decreased physiologic reserve, may be common and clinically significant in this population, yet remains insufficiently characterised. We aim to determine the prevalence and characteristics of frailty among adults with cardiac amyloidosis, and examine its association with functional status, quality of life, and disease severity.
Methods & Design:
As a prospective, observational, single-centre cohort study, adults with confirmed cardiac amyloidosis will undergo standardised frailty assessment. The prevalence of physical frailty (≥3 criteria) and cognitive frailty (≥2 frailty criteria plus mild cognitive impairment (MoCA <26)) will be evaluated, and the distribution of individual criteria summarised. Disease characterisation will include functional status, quality of life, disease staging, and biomarkers at baseline and 12-month follow-up. Associations between frailty and clinical variables will be explored using descriptive and univariate analyses.
Expected Results:
We anticipate a high prevalence of frailty among individuals with cardiac amyloidosis, with greater frailty burden associated with worse functional status, diminished quality of life, multisystem disease and advanced disease severity.
Conclusions:
The study will deliver a pragmatic, clinically aligned characterisation of frailty in cardiac amyloidosis and support the development of hypotheses to guide the design of future longitudinal and interventional studies in cardiac amyloidosis.
More Related Videos
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification